Prognostic utility of pre‐transplantation [18F] fluorodeoxyglucose positron emission tomography/computed tomography in patients with diffuse large B‐cell lymphoma who underwent rituximab, dexamethasone, high‐dose cytarabine, carboplatin salvage chemotherapy. (6th August 2019)

• Record Type: Journal Article
• Authors: Mesguich, Charles; Roch, Alexandre; Hindié, Elif; Milpied, Noël; Bordenave, Laurence; Tlili, Ghoufrane; Bouabdallah, Krimo
• Is Part Of: British journal of haematology. Volume 188:Number 2(2020)
• Page Start: 268
• Page End: 271
• Publication Date: 2019-08-06
• Subjects: positron emission tomography/computed tomography -- diffuse large B‐cell lymphoma -- 18‐ fluorodeoxyglucose -- autologous stem cell transplantation -- transplant; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.16144
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: We analysed the outcomes of 62 patients with refractory/relapsed diffuse large B‐cell lymphoma (rrDLBCL) who had pre‐transplantation fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) after R‐DHAC (rituximab, dexamethasone, high‐dose cytarabine, carboplatin) salvage chemotherapy, and were evaluated using Deauville criteria and total lesion glycolysis (TLG). A positive pre‐transplantation PET/CT with Deauville score of 5 was associated with shorter progression‐free survival (PFS) ( P = 0·01), while a Deauville score of 4 was not predictive of outcome. Only pre‐transplant TLG was significantly associated with both PFS ( P = 0·005) and overall survival ( P = 0·03). TLG deserves to be further investigated in prospective studies.